MENU
+Compare
LXRX
Stock ticker: NASDAQ
AS OF
Jan 30 closing price
Price
$0.82
Change
-$0.01 (-1.20%)
Capitalization
298.34M

LXRX Lexicon Pharmaceuticals Forecast, Technical & Fundamental Analysis

a company, which engages in discovery and development of breakthrough treatments for human disease

Industry Biotechnology
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for LXRX with price predictions
Jan 08, 2025

LXRX in +17.92% Uptrend, growing for three consecutive days on January 07, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where LXRX advanced for three days, in of 204 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 02, 2025. You may want to consider a long position or call options on LXRX as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

LXRX broke above its upper Bollinger Band on January 06, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.659) is normal, around the industry mean (15.749). P/E Ratio (0.000) is within average values for comparable stocks, (88.784). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.848). LXRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (45.662) is also within normal values, averaging (276.027).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. LXRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

LXRX is expected to report earnings to fall 34.44% to -11 cents per share on March 12

Lexicon Pharmaceuticals LXRX Stock Earnings Reports
Q4'24
Est.
$-0.12
Q3'24
Missed
by $0.02
Q2'24
Beat
by $0.01
Q1'24
Est.
$-0.20
Q4'23
Beat
by $0.02
The last earnings report on November 12 showed earnings per share of -18 cents, missing the estimate of -15 cents. With 4.35M shares outstanding, the current market capitalization sits at 298.34M.
A.I. Advisor
published General Information

General Information

a company, which engages in discovery and development of breakthrough treatments for human disease

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
2445 Technology Forest Boulevard
Phone
+1 281 863-3000
Employees
285
Web
https://www.lexpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JGMAX26.210.30
+1.16%
Janus Henderson Triton A
QIACX48.24N/A
N/A
Federated Hermes MDT All Cap Core IS
PIGDX14.78N/A
N/A
Federated Hermes International Growth IS
TCGLX52.25N/A
N/A
Touchstone Large Company Growth C
PAILX7.95N/A
N/A
PGIM Jennison Intl Sm-Md Cap Opps C

LXRX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with EPIX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then EPIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
-0.71%
EPIX - LXRX
45%
Loosely correlated
+1.17%
FRTX - LXRX
41%
Loosely correlated
+0.32%
VCYT - LXRX
37%
Loosely correlated
+3.83%
NTLA - LXRX
36%
Loosely correlated
+3.85%
ABCL - LXRX
36%
Loosely correlated
+0.94%
More